Colon buying weed

__________________________

📍 Verified store!

📍 Guarantees! Quality! Reviews!

__________________________

▼▼ ▼▼ ▼▼ ▼▼ ▼▼ ▼▼ ▼▼

▲▲ ▲▲ ▲▲ ▲▲ ▲▲ ▲▲ ▲▲

Colon buying weed

Official websites use. Share sensitive information only on official, secure websites. Address correspondence to: Iain S. Medicinal cannabis MC is an increasingly utilized treatment option for various refractory diseases. Understanding this use and associated outcomes may help inform future clinical trials. A cross-sectional anonymous online survey was conducted involving Australians with IBD. The survey included validated sub-questionnaires assessing quality of life, medication adherence, IBD severity, and functional impairment. A total of responses were obtained. Results showed Half of the current users also consumed cannabis recreationally although less frequently than for medicinal purposes. Cannabis consumption was via smoking joints Only 3 respondents reported using legally accessed products. Clinical ratings of IBD severity did not differ according to cannabis use although users reported more hospitalizations, less engagement with specialist services, and lower medication adherence. IBD symptoms reported as positively affected by cannabis included abdominal pain, stress, sleep, cramping, and anxiety. Most users Cannabis-using ulcerative colitis patients reported better quality of life than nonusers on some measures. Further clinical trials are required to validate, or refute, patient claims around MC efficacy for symptom control in IBD. The incidence of inflammatory bowel disease IBD continues to rise in Western countries 1 and while many symptoms can be managed with medical therapy, there is consensus that IBD is not readily curable with available therapeutic strategies. As the current therapeutic options frequently leave patients with imperfect symptom control, IBD patients often experience a difficult trajectory and frequently seek alternative treatment options to manage their symptoms. Medicinal cannabis products are usually in the form of botanical material that is smoked or vaporised, or orally consumed extracts oils. Synthetic THC dronabinol and a chemically related analog nabilone are approved in some countries for use in chemotherapy-induced nausea and vomiting and AIDS-associated anorexia, while a mixture of plant-derived THC and CBD nabiximols is approved for treating spasticity in multiple sclerosis. The increased interest in the use of MC products for treating IBD reflects the more widespread community interest in MC products that is linked to their increased legal availability in many countries. It is also predicated on observed endocannabinoid influences on gastrointestinal function 11 and encouraging findings of anti-inflammatory and wound healing effects of plant-derived cannabinoids in animal and cellular models of IBD. Clinical trials of MC products, however, have produced only mixed outcomes to date. Finally, a recently conducted observational study 17 involving prescribed MC products predominantly raw cannabis plant material and THC:CBD containing products showed reduced disease severity as measured by the Harvey-Bradshaw Index following a longitudinal assessment 12 months postinitiation of MC treatment. These ambivalent clinical trial outcomes could reflect an intrinsic lack of cannabinoid efficacy or other factors such as choice of cannabinoid product, dosing regimen, route of administration, and lack of statistical power. In any case, such results do not seem to deter patient motivations to utilize MC. With Australia having one of the highest international incidence rates of IBD This included exploring the demographic and clinical characteristics of MC users versus nonusers, their experience with MC products, and perspectives on regulatory and legal issues, as well as identifying factors predicting cannabis use and symptomatic improvement in this population. Eligible participants were aged at least 18 years, received healthcare in Australia, and provided voluntary informed consent. There was no requirement for participants to currently use, have previously used, or considered using MC. Participants completed the survey only once. An item survey was produced that incorporated original questions and a number of existing validated instruments. The survey consisted of the following items:. SIBDQ scores range from 10 to Utility scores were calculated using Australian coefficients. A MARS score of 0—10 was calculated with 10 indicating the best possible medication adherence. Items g , h , and i were included to explore disease severity in respondents. Given the survey was administered online and not in a clinical setting, these items were modified to omit components that would normally be assessed by a physician. The modified disease indices are described in Supplementary Table S2. The additional questions enquired about IBD symptoms for which cannabis was used, as well as perceived efficacy, side effects, preparation type, source, and frequency of cannabis use. All participants were asked for their opinions on regulatory issues relating to MC access in Australia. Gastroenterologists specializing in the treatment of IBD provided expert input and a review of the survey questions. MC online discussion groups and forums were not included in our direct recruitment strategy to limit bias in data collection and patient sampling. There was no reimbursement or financial incentive for taking part in the voluntary survey. At the end of the survey respondents were asked if they would like to be contacted for future clinical trials. If agreeable, they were provided a secure nonlinked platform to enter their contact details. Examples of the advertisements used to invite survey respondents via IBD patient networks are provided as Supplementary Materials. The survey data were also analyzed for correlations between responses to specific questions ie, Are you under the care of a specialist? These calculations were completed using the statsmodels Python library. Univariate analysis was conducted to explore factors predicting cannabis use in the survey cohort. Odds ratios were determined based on the survey question: Have you ever used cannabis to manage your IBD symptoms? Odds ratios were determined based on the question: Do you consider medicinal cannabis successful in managing your IBD symptoms? This term is used as generally understood by laypeople in the community, namely, the use of cannabis to treat a specific disease or condition, as opposed to the recreational use of cannabis. The term does not imply that the use of cannabis has been authorized or prescribed by a medicinal practitioner, or that there is any evidence of cannabis being efficacious for a particular condition. Under current legal MC access schemes in Australia, the TGA approves formal clinician requests for access to specific unregistered MC products for patients with specific refractory conditions. Under the Freedom of Information Act 32 individuals may legally request access to government documents. We have routinely submitted Freedom of Information requests for access to current Australian MC prescribing data from the TGA to monitor the indications for which MC is being approved and numbers of approvals over time. All participants were required to acknowledge they had read the linked Participant Information Statement and to confirm their consent to the study before initiating the survey through REDCap. A total of respondents consented and initiated a survey response. Respondents were asked if they currently use or had previously used cannabis to manage their IBD: Percentage of respondents is reported for each item. Demographic characteristics of the survey population are reported in Table 1 according to the cannabis use category current, previous, or nonuser. Responses were received from all Australian states and territories. The majority of respondents were employed Participants reported hearing about the survey primarily through Facebook CD was the most frequently reported type of IBD Clinical disease severity as measured by modified disease activity indices Supplementary Table S3 was not significantly different between users and nonusers of cannabis in any of the IBD categories Table 2. Cannabis users had a lower MARS medication adherence score compared to nonusers 6. Overall, users had a lower prevalence of use of pharmaceutical drugs Bolded values indicate the majority satisfaction level for each user group within in each drug class. Number of respondents for each group varies based on the number having experience with that pharmaceutical class. However, the reported rates of use of these 2 classes of drug were higher in cannabis users than nonusers The most common routes of cannabis administration were via smoking a joint Percentage of total respondents shown for this item. Current users accessed their cannabis through a recreational dealer Only 3 respondents were using the legal pathways provided by the Australian government. Current users medicated with cannabis near-daily current users mean Recreational use tended to be less frequent than medicinal use mean An overwhelming majority of all users current and previous combined reported their IBD had improved since using cannabis UC A few CD respondents mostly previous users; 6. Respondents reported greatest improvements in abdominal pain, stress, sleep issues, cramping, and anxiety with cannabis use, with the least improvement in obstructive symptoms, rectal bleeding, and fatigue Figure 2. Symptomatic relief varied with IBD types. Within the top 5 improved symptoms, anxiety was common across all IBD types. Self-reported IBD symptom change with medicinal cannabis use in current and previous users listed by greatest positive benefit to least. Percentage of total respondents shown. There was little overall reported change in the use of antidepressants, anxiolytics, and biologic agents with cannabis use, with the majority Data listed by greatest drug reductions to least. Number of respondents for each drug class varies based on the number of current cannabis users taking that class of drugs concomitantly. Table 4 shows the results of univariate analysis of factors determining a positive response to the question: Have you ever used cannabis to manage your IBD symptoms? Hospitalization from complications relating to IBD was a predictor of use, as was lifetime hospitalizations of greater than 10 times for IBD. Lack of any current pharmaceutical drug regimen for IBD management was a strong predictor of use, as was a lack of engagement with a gastroenterological specialist. Unsurprisingly, current cannabis use was a positive predictor of perceived benefit, while being a previous user was a negative predictor. Education level predicted use and also perceived benefit, with those having completed a university degree being less likely to report benefits of cannabis. Table 5 shows the side effects experienced by current and previous users. There were very few severe or intolerable side effects reported although mild and tolerable side effects were common. Previous users cited difficulty accessing cannabis as the main reason for discontinuing use Other factors driving cessation of use included concerns around illegality Nonetheless, as noted above, significantly more side effects were experienced by previous users than current users, suggesting this may be an important factor Table 5. Only 2 respondents both users, 0. This level of willingness may not therefore be reflective of the broader Australian IBD cohort. To our knowledge, this is the largest survey to date on cannabis use in patients with IBD. Overall, cannabis users seemed less likely to be engaged in clinical treatment for their IBD, with less likelihood of being under specialist care, lower likelihood of pharmaceutical drug use, and poorer medication adherence. Lack of engagement with conventional care in MC users might be explained in several ways. One is that a proportion of patients with refractory disease who may have trialed many existing evidence-based options have, in some ways, given up on conventional medications and are exploring alternatives such as MC. It may also be the case that patients who have never been well engaged in clinical care are utilizing MC as a substitute for prescription medications. We did not collect data to indicate that refractory patients had exhausted all approved options before trialing MC. In other studies MC use was predicted by greater severity and chronicity of disease, presumably motivating a desperate search for alternative therapies. This is consistent with at least one previous report. Increased numbers of hospitalizations for IBD may infer increased disease severity although it is notable that current MC users did not differ in current disease severity compared to nonusers based on the survey responses. The alternative possibility is that less engagement with clinical care and poor medication adherence drives increased hospitalizations in MC users. Epidemiological studies report that recreational cannabis use in IBD patient cohorts was associated with reduced length of hospital stays and less hospital charges as a result. Reports assessing the effect of cannabis legalization as a proxy for increased community cannabis use on hospitalizations suggests neutral effects. Cannabis users self-reported significant symptomatic relief with improvements in abdominal cramping and pain. This agrees with previous reports in CD patients using cannabis 21 and has a plausible mechanistic basis. It is also worth considering whether reduced use of pharmaceuticals with significant side effect burdens Figure 3 may also explain symptomatic improvements in cannabis users. Reported reductions in the use of key IBD drug classes ie, immunomodulators, aminosalicylates, and corticosteroids in cannabis users agree with the results of a recent observational report of IBD patients using legally prescribed MC, 17 supporting this possibility. These may be a significant impediment to long-term use of MC in IBD and other conditions, as is widely acknowledged. Despite the self-reported symptomatic improvement, QoL showed a complex relationship with cannabis use within our survey cohort Table 2 , Supplementary Table S2. However, in neither case were these small changes in EQ-5D scores supported by a difference in the health-specific QoL measure, SIBDQ, suggesting these differences may not be clinically meaningful. Furthermore, interpretation of these findings is challenging: by sampling at only a single time point it is difficult to infer if QoL differed at baseline user and nonuser groups or whether it has been affected by MC use. It is notable that significant improvements in QoL have been reported in 2 clinical trials of cannabis for IBD 44 and in advanced cancer patients, 45 including anecdotal reports from these trials of improved appetite and sleep—which supports our findings on symptom improvement Figure 2. Finally, it should be noted that the magnitude of self-reported symptom improvement in the present survey was surprisingly high. Symptom improvements of the magnitude reported in this study are rarely seen in any therapeutic intervention and do not easily align with the existing randomized controlled trial results of cannabinoids in IBD cohorts. This emphasizes the need for independent clinical validation of the symptom improvements reported by respondents and raises the possibility of some selection bias within the study cohort. Cannabis users in our study cohort tended to be male, Caucasian, non-university educated, and tobacco smokers; all factors known to predict recreational cannabis use. The most common source of cannabis was through a recreational dealer, further blurring the delineation between medicinal and recreational use. This again highlights differences between purposive current users, interested nonusers, and those using cannabis medicinally as a result of preexisting recreational use. Targeted surveys of patients receiving MC through the legal government scheme would be the ideal sample to evaluate perceived benefit, as the content and dose of the product are regulated and verifiable, and there is clinical supervision and evaluation of their MC use. Notably, only 3 respondents reported accessing cannabis products from official sources, consistent with contemporary criticism of access pathways in Australia. There are several limitations to our survey to acknowledge. Anonymous, open-access, online surveys have inherent limitations related to sampling bias, reliability of responses, and an inability to verify the clinical diagnosis and disease severity. From the knowledge gained it is likely there are 2 populations of IBD patients with overlapping use patterns and clinical features using MC. While preclinical investigations continue into novel cannabinoids and their potential to treat the underlying IBD pathophysiology, it is important that clinical investigations into the ability of adjunct MC to reduce symptom burden in IBD populations continue to validate or refute patient claims. This is especially prudent as there are now legal access pathways for regulated quality MC products in Australia. We also thank the Taylor family for inspiring this survey. Author Contributions M. All authors reviewed and approved the final manuscript. Conflicts of Interest: M. In addition, I. This section collects any data citations, data availability statements, or supplementary materials included in this article. As a library, NLM provides access to scientific literature. Crohns Colitis Find articles by Melissa J Benson. Find articles by Sarah V Abelev. Find articles by Susan J Connor. Find articles by Crispin J Corte. Find articles by Lewis J Martin. Find articles by Lucy K Gold. Find articles by Anastasia S Suraev. Find articles by Iain S McGregor. Received Nov 21; Collection date Apr. Open in a new tab. Click here for additional data file. Similar articles. Add to Collections. Create a new collection. Add to an existing collection. Choose a collection Unable to load your collection due to an error Please try again. Add Cancel.

Marijuana and colorectal cancer: Does weed help?

Colon buying weed

Medical marijuana is a therapeutic drug with numerous beneficial traits for health. Its legalized status in Florida after Amendment 2 has enabled thousands of patients to utilize its medicinal effects. Today, the Office of Medical Marijuana Use regulates the use of marijuana in Florida, and patients with certain illnesses can benefit from this drug. However, you must get your valid medical marijuana card in Melbourne to ensure legal compliance with medical marijuana laws in the state. This article will explain what irritable bowel syndrome is and how you can use MMJ to manage this illness while complying with Florida marijuana laws. Currently diagnosed using the Rome IV criteria, irritable bowel syndrome IBS is a prevalent illness marked by abnormal bowel motions and abdominal discomfort. It appears that twice as many women as men have IBS. Before turning 40, the majority of IBS sufferers experience their first symptoms. Numerous IBS sufferers claim to have a family member who exhibits similar symptoms. Post-infectious IBS is the term for the less common scenario in which IBS symptoms arise following a severe intestinal illness. IBS is a severe intestinal illness that can cause moderate to severe pain in the stomach. Regretfully, IBS has no known remedy as of now, but evidence suggests that medical marijuana could provide relief from the pain and help to cope with some symptoms linked with IBS. IBS can be divided into four subtypes, all of which are equally common:. Emotional strain, certain meals consumed, constipation, or diarrhea can all cause the pain. Additional indications of IBS involve:. Doctors may prescribe medications, probiotics, dietary changes, and mental health therapy to manage irritable bowel syndrome. You should try a few ways to determine which treatment is most effective. Nevertheless, you must consult your physician to choose the best action. Moreover, IBS symptoms can be brought on by a variety of factors, such as certain meals, medications, the presence of gas or feces, and mental stress. Thus, discussing your health issue with a doctor who can aid you in taking the proper medication and adjusting your lifestyle is necessary. IBS treatment aims to ease the symptoms and improve the quality of life. Thus, you can do the following to avoid the challenging symptoms of IBS:. As the symptoms of IBS can be challenging to manage, having the condition can be frustrating. Although the illness and its symptoms can be managed with some prescription drugs, the relief these medications provide is often insufficient and unsatisfactory. Thus, people with IBS are turning to alternative therapies, like marijuana, for natural relief and better life quality. The cannabis sativa plant, hemp, is cultivated primarily for its dried leaves, flowers, and, less frequently, seeds and stems. The primary psychoactive compound in marijuana is deltatetrahydrocannabinol THC , a cannabinoid that produces mind-altering effects. THC and CBD , two significant cannabinoids in marijuana, can influence various functions controlled by the endocannabinoid system ECS , such as mood, hunger, and sleep. Moreover, the cannabis plant naturally contains over a hundred different cannabinoids, which interact with receptors throughout the body to maintain balance. Moreover, these receptor types are distributed throughout the body, including the gastrointestinal tract and central nervous system. Cannabidiol CBD is another component of marijuana with potential therapeutic benefits. Moreover, based on a study , Marinol dronabinol , a synthetic form of THC, has shown promise in managing irritable bowel syndrome IBS-D and alternating IBS by reducing gut transit and improving colonic function. Marijuana may also help alleviate IBS symptoms by influencing opioid, cholinergic, and cannabinoid receptors. However, medical marijuana research about IBS is in its infancy, and more introspection is needed in this area. Medical marijuana use can lead to adverse effects if taken without the guidance of an MMJ expert. It can cause cognitive issues with detrimental effects on judgment, focus, memory, and balance, lung damage, elevated risk of heart attack, issues related to mental health, etc. Thus, patients who are interested in using medical marijuana must contact a medical marijuana doctor who can offer guidance on MMJ. Moreover, you must get your medical marijuana card to buy MMJ products. Medical marijuana card attainment is a necessary process towards legal compliance for marijuana. Thus, the card acquisition process involves the given steps:. Medical marijuana is a therapeutic drug with various health benefits for IBS symptoms. Its constituents can prove to be effective for IBS management. However, you must get your medical marijuana card for safe and compliant MMJ use. Consequently, if you reside in Florida, we at My Florida Green can assist you in getting your card and begin using medical marijuana for Irritable Bowel Syndrome. Welcome to our medical marijuana podcast library, where you will find insightful discussions, expert interviews, and the latest trends in the field. Through our podcasts, hosted by leading medical marijuana experts, we aim to empower you on your medical marijuana journey. Whether you are a patient, healthcare professional, or simply curious about the uses and benefits of medical marijuana, our podcasts are designed to educate, inform, and inspire. We deliver premium care and work to build lasting relationships with our customers by offering the best service in the business. We have been helping patients navigate medical marijuana in Florida since the passing of legislation in and have already helped over 43, qualified patients obtain their Florida Medical Marijuana Cards. Medical Marijuana for Irritable Bowel Syndrome. Medical Marijuana. What is IBS? Mostly IBS-C, or constipation and abdominal pain. Switching between constipation and loose stools with pain in the abdomen IBS-mixed. IBS-U undefined subtype ; symptoms can vary. Symptoms of IBS Emotional strain, certain meals consumed, constipation, or diarrhea can all cause the pain. Additional indications of IBS involve: Stool mucus Sense that the evacuation is not complete Headaches caused by migraines Difficulties sleeping Depression or anxiousness fibromyalgia condition Persistent pelvic discomfort Navigating Conventional Treatment Doctors may prescribe medications, probiotics, dietary changes, and mental health therapy to manage irritable bowel syndrome. Thus, you can do the following to avoid the challenging symptoms of IBS: Know the food triggers that make your symptoms worse consume meals that are high in fiber stay hydrated Get enough sleep Engage in regular exercise As the symptoms of IBS can be challenging to manage, having the condition can be frustrating. Medical Marijuana for IBS The cannabis sativa plant, hemp, is cultivated primarily for its dried leaves, flowers, and, less frequently, seeds and stems. Method of getting an MMJ card Medical marijuana card attainment is a necessary process towards legal compliance for marijuana. Prev Post. Next Post. Search Search for:. Recent Post. Medical Cannabis and your health: Top 10 ways to reduce risks. Curious about the benefits of Medical Marijuana but unsure of where to start? Get notified when a new podcast is released. Start Listening Today! Follow Us.

Colon buying weed